aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

Core Viewpoint - A new class action lawsuit has been filed against aTyr Pharma, Inc. and its executives, expanding the alleged class period for investors who suffered losses from November 7, 2024, to September 12, 2025, due to misleading statements about the drug Efzofitimod [1][2][4]. Group 1: Class Action Details - The lawsuit, King v. aTyr Pharma Inc., seeks to represent all individuals and entities who acquired aTyr Pharma securities during the expanded class period [2]. - The previous class period began in January 2025, making this expansion significant for investors who purchased shares in late 2024 [2]. - The lead plaintiff deadline for the class action is set for December 8, 2025 [4]. Group 2: Allegations Against aTyr Pharma - The allegations center around aTyr's Phase 3 clinical trial, EFZO-FIT, which evaluated the drug Efzofitimod for patients with pulmonary sarcoidosis [5]. - Executives allegedly made overly positive statements about the drug's efficacy while concealing material adverse facts regarding its ability to reduce steroid dependency [6][7]. - The lawsuit claims that these misrepresentations constitute securities law violations, misleading investors about the drug's true prospects [7]. Group 3: Impact of the Allegations - The truth about the drug's efficacy was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a significant drop in stock price [8][9]. - Following the announcement, aTyr's stock plummeted from $6.03 to $1.02 per share, marking an 83.2% decline in a single day [9]. - The company acknowledged the setback and indicated plans to engage with the FDA for a path forward [9]. Group 4: Investigation and Legal Support - Hagens Berman, a prominent shareholders rights firm, is investigating whether aTyr misled investors regarding the drug's data and trial design [10]. - The firm encourages investors who suffered losses to submit their claims and offers support for whistleblowers with non-public information [11].